Syngene International Ltd is Rated Sell

Current Rating and Its Significance

MarketsMOJO currently assigns Syngene International Ltd a 'Sell' rating, indicating a cautious stance towards the stock. This rating suggests that investors should consider reducing exposure or avoiding new purchases at present, given the company's valuation and financial trends. The rating was revised on 08 December 2025, moving from a 'Strong Sell' to a 'Sell' as the company’s overall score improved modestly from 28 to 34. Despite this improvement, the stock remains unattractive relative to market benchmarks and peers.

Here’s How Syngene International Ltd Looks Today

As of 05 January 2026, Syngene International Ltd’s financial and market data reveal a mixed picture. The company’s Mojo Score stands at 34.0, reflecting a cautious outlook. The stock has shown some short-term resilience with a 1-day gain of 0.78%, a 1-month increase of 3.62%, and a 3-month rise of 4.19%. However, over the past year, the stock has delivered a negative return of -22.78%, underperforming broader indices such as the BSE500 over multiple time frames.

Quality Assessment

Syngene International Ltd’s quality grade is rated as 'good', indicating that the company maintains a solid operational foundation. Over the last five years, net sales have grown at an annualised rate of 12.63%, while operating profit has increased by 9.01% annually. These figures suggest steady, albeit moderate, growth. However, recent quarterly results have been disappointing, with the September 2025 quarter showing a 47.1% decline in profit after tax (PAT) to ₹67.10 crores compared to the previous four-quarter average. Operating profit to interest coverage also hit a low of 15.11 times, and PBDIT dropped to ₹199.50 crores, signalling near-term operational challenges.

Valuation Considerations

The valuation grade for Syngene International Ltd is 'very expensive'. The stock trades at a price-to-book value of 5.6, which is significantly higher than the average valuations of its peers. This premium valuation is not fully supported by the company’s return on equity (ROE) of 9.9%, which is moderate but not exceptional. Furthermore, the price-to-earnings-to-growth (PEG) ratio stands at an elevated 38.5, indicating that the market price is high relative to the company’s earnings growth prospects. Such valuation metrics suggest that the stock may be overvalued, increasing the risk for investors.

Financial Trend Analysis

The financial trend for Syngene International Ltd is currently negative. Despite moderate long-term growth in sales and operating profit, recent quarterly results have shown a marked decline in profitability. The company’s PAT fell sharply in the latest quarter, and operating profit margins have contracted. This negative trend is reflected in the stock’s underperformance relative to the BSE500 index over the last one year, three years, and three months. The subdued financial momentum raises concerns about the company’s ability to sustain growth and profitability in the near term.

Technical Outlook

Technically, the stock is graded as 'mildly bearish'. While short-term price movements have shown some gains, the overall technical indicators suggest a cautious stance. The stock’s recent performance has not demonstrated strong upward momentum, and the mildly bearish technical grade aligns with the negative financial trend and expensive valuation. Investors should be wary of potential volatility and limited upside in the current market environment.

Summary for Investors

In summary, Syngene International Ltd’s current 'Sell' rating reflects a combination of factors. The company maintains good operational quality but faces challenges in financial performance and valuation. Its very expensive valuation, negative financial trend, and mildly bearish technical outlook suggest limited near-term upside and elevated risk. Investors should carefully consider these factors when evaluating their exposure to the stock, particularly given its underperformance relative to broader market indices.

Investor Takeaway

For investors, the 'Sell' rating on Syngene International Ltd serves as a cautionary signal. While the company has demonstrated some resilience in sales growth and maintains a good quality grade, the combination of expensive valuation, deteriorating financial trends, and subdued technical indicators suggests that the stock may not be an attractive investment at this time. Those holding the stock should consider their risk tolerance and portfolio objectives carefully, while prospective investors might look for more favourable entry points or alternative opportunities within the healthcare services sector.

Market Context and Sector Positioning

Syngene International Ltd operates within the healthcare services sector, a space that often commands premium valuations due to growth potential and defensive characteristics. However, the company’s current valuation appears stretched relative to its financial performance and peer group. The stock’s small-cap status also implies higher volatility and risk, which investors should factor into their decision-making process. The broader market environment remains dynamic, and investors should monitor sector trends and company-specific developments closely.

Conclusion

In conclusion, Syngene International Ltd’s 'Sell' rating by MarketsMOJO, last updated on 08 December 2025, reflects a comprehensive assessment of quality, valuation, financial trends, and technical factors as of 05 January 2026. The stock’s current fundamentals and market signals suggest caution, with limited upside potential and elevated risks. Investors are advised to weigh these insights carefully in the context of their investment strategy and market outlook.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today